The company develops orthopedic implants and stents for feet and ankle surgery, aiming to address the root problem rather than just treating symptoms. Their product portfolio includes the HyProCure TaloTarsal Stabilization device, the osteo-WEDGE Open Wedge Bone Locking system, and the Soleus Foot Care Collection. GraMedica oversees research, production, and worldwide support, while also raising awareness about talotarsal displacement. Through the Graham International Implant Institute (GIII), the company educates foot and ankle surgeons on effective treatment solutions. GIII offers online and hands-on training seminars and lectures in North America and Europe. GraMedica remains committed to its mission of changing lives through continuous development of new product lines.